Anzeige
Mehr »
Login
Donnerstag, 23.09.2021 Börsentäglich über 12.000 News von 673 internationalen Medien
Dieser Pennystock wird zum Dividendenzahler?! Heute plausibler denn je!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PPX6 ISIN: US72941H4002 Ticker-Symbol: XMPA 
Frankfurt
23.09.21
08:04 Uhr
1,656 Euro
-0,024
-1,43 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,6461,72410:18
1,6581,72410:17

Aktuelle News zur PLUS THERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
DiPLUS THERAPEUTICS, INC. - 8-K, Current Report1
13.09.PLUS THERAPEUTICS, INC. - 8-K, Current Report-
13.09.Plus Therapeutics Inc.: Plus Therapeutics Announces the Appointment of Industry Veteran, Norman LaFrance, M.D., as the Company's Chief Medical Officer1
08.09.Plus Therapeutics Inc.: Plus Therapeutics to Present at the H.C. Wainwright Global Investment Conference-
03.09.PLUS THERAPEUTICS, INC. - S-1, General form for registration of securities1
02.09.Plus Therapeutics jumps 17% on manufacturing deal for Rhenium-186 NanoLiposome5
23.08.Why Is Plus Therapeutics Stock Rising After Data Presentation From Brain Tumor Trial?5
21.08.Plus Therapeutics Inc.: Plus Therapeutics Announces Presentation of Data from the ReSPECT-GBM Trial and Plans for Treating Pediatric Brain Cancer5
19.08.Plus Therapeutics reports encouraging 186RNL data in leptomeningeal metastases3
19.08.Plus Therapeutics Shares Preclinical Data For Targeted Cancer Radiation Therapy: Highlights-
19.08.Plus Therapeutics Inc.: Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for ...2
13.08.Plus Therapeutics Inc.: Plus Therapeutics to Present Data from ReSPECT-GBM Trial at the American Association of Neurological Surgeons 2021 Annual Scientific ...3
11.08.ACY, PSTV among mid-day movers2
11.08.Plus Therapeutics Inc.: Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome5
05.08.Plus Therapeutics Inc.: Plus Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference6
27.07.Plus Therapeutics Inc.: Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement9
23.07.Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q2 2021 Results - Earnings Call Transcript2
22.07.EARNINGS SUMMARY: Details of Plus Therapeutics Inc. Q2 Earnings Report263WASHINGTON (dpa-AFX) - Below are the earnings highlights for Plus Therapeutics Inc. (PSTV):-Earnings: -$2.80 million in Q2 vs. -$1.84 million in the same period last year. -EPS: -$0.25 in...
► Artikel lesen
22.07.Plus Therapeutics Shares Jump As First Patient Treated In Latest Cohort Of Brain Tumor Trial2
22.07.SOS, ITRM and PSTV among premarket gainers1
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1